Digital blood coagulation: scientists from Bayer HealthCare and Bayer Technology Services can investigate the action of drug products even without a laboratory, centrifuges or test tubes. To do this, they use a computer model that virtually simulates the processes in the blood vessels down to the smallest detail. The results make it easier to decide, for example, whether development of an active ingredient should be continued or at which dosage a new substance should be tested.
Testing digital blood samples
The simulation software allows Bayer’s scientists to plan clinical trials more accurately and thus efficiently, saving a great deal of time in the launch of new drug products. At present, the medical experts and computer specialists are modifying their software for a new assignment: they want to use it to be able to predict the effects of Bayer's anticoagulant with the active ingredient rivaroxaban in children as well.